Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-15

Clinical Trial Update: SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Singulair (montelukast) as a complementary therapy for asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SINGULAIR (montelukast)

Snippet

Sponsor: Organon and Co | Conditions: Asthma | Phase 3 | Status: COMPLETED